Managing Chemotherapy-Induced Peripheral Neuropathy: Clinical Observations with ALA & B-Complex Supplementation

5 hours ago
Managing Chemotherapy-Induced
Peripheral Neuropathy: Clinical Observations with
ALA & B-Complex Supplementation
Chemotherapy-induced peripheral neuropathy (CIPN) is a clinically important toxicity of platinum- and taxane-based chemotherapy, as persistent pain, paraesthesia, numbness and sensory disturbances may impair daily functioning and lead to dose reduction or treatment discontinuation. A meta-analysis of 4,179 patients reported CIPN prevalence of 68.1% within the first month, 60.0% at three months and 30.0% at six months or later. Its pathophysiology involves oxidative stress, mitochondrial dysfunction, axonal injury, Schwann cell dysfunction and myelindisruption2. Given the limited preventive options, nutritional support targeting oxidative stress and neuronal metabolism warrants investigation. 
Sponsored as an educational program by BREGO Life Sciences Sdn Bhd

Resources

MY-BRE-002c: Managing Chemotherapy-Induced Peripheral Neuropathy: Clinical Observations with ALA & B-Complex Supplementation MY-BRE-002c: Managing Chemotherapy-Induced Peripheral Neuropathy: Clinical Observations with ALA & B-Complex Supplementation

MY-BRE-002c: Managing Chemotherapy-Induced Peripheral Neuropathy: Clinical Observations with ALA & B-Complex Supplementation